Update Session: Triple-Negative and HER2-Positive Breast Cancer

Servei d’Oncologia de l’HUSJR i l’Institut d’Investigació Sanitària Pere Virgili (IISPV)

🎗️ Update Conference on Her2-Positive and Triple-Negative Breast Cancer

Despite advances in the diagnosis and treatment of breast cancer, the Her2-positive and triple-negative subtypes remain a significant clinical challenge. These are biologically more aggressive forms, with a higher risk of recurrence and a clear need for personalized therapy.

Recent years have brought significant improvements in the molecular understanding of these tumors and in access to targeted treatments. Nevertheless, their management continues to demand ongoing updates and a multidisciplinary approach.

From clinical research to real-world application, innovation in these subtypes is key to improving survival rates and quality of life for patients.

📅 With this conference, we propose an update focused on Her2-positive and triple-negative breast cancer. We will review diagnostic advances, therapeutic strategies, and clinical cases that will help us anticipate new scenarios and optimize decision-making in everyday clinical practice.